The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2024 | Entinostat with nivolumab in pancreatic ductal adenocarcinoma
Marina Baretti, MD, Johns Hopkins University School of Medicine, Baltimore, MD, discusses findings from a Phase II trial (NCT03250273) of entinostat with nivolumab in pre-treated patients with pancreatic ductal adenocarcinoma (PDAC). 27 evaluable patients were enrolled and the overall response rate, which was the primary endpoint, was not met. However, the therapeutic approach may provide promising responses in a group of patients with limited treatment options. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
